Department of Ophthalmology, Ophthalmic Plastic Surgery, Lions Eye Institute, Albany Medical College, Slingerlands, New York 12159, USA.
Ophthalmic Plast Reconstr Surg. 2012 Nov-Dec;28(6):416-8. doi: 10.1097/IOP.0b013e3182627ebc.
Rosacea is a significant cause of ocular surface disease, and our current therapeutic armamentarium is often ineffective. Intraductal meibomian gland probing is a novel technique to address dry eye syndrome, although its use has not been described in the management of ocular surface disease from rosacea.
Patients with ocular rosacea, meibomian gland dysfunction, and surface disease, which was refractory to conventional management, underwent intraductal meibomian gland probing. Each patient completed the Ocular Surface Disease Index (OSDI) questionnaire before the procedure and at the 1- and 6-month postoperative visits.
Forty eyelids of 10 patients (5 men, 5 women; mean age = 42.1 years) underwent intraductal meibomian gland probing. All patients reported subjective improvement in their symptoms of discomfort, tearing, and blurred vision. The mean preoperative, 1-month, and 6-month OSDI scores were 78.11 (standard deviation [SD] = 5.33), 37.54 (SD = 7.25), and 43.00 (SD = 5.49), respectively. The differences between the preoperative and one- and six-month scores were statistically significant (p < 0.05). Nine of the ten patients in this study were able to discontinue their doxycycline use after surgery, and 10 out of 10 patients reported decreased frequency of artificial tear use. No complications were identified in the 6-month follow-up period.
Intraductal meibomian gland probing is a safe, effective technique to address the ocular surface disease, tearing, and discomfort associated with ocular rosacea, and this intervention results in a dramatic improvement in these symptoms. This study provides the first documentation of these findings and represents the first quantitative demonstration of the use of intraductal meibomian gland probing in the peer-reviewed literature.
酒渣鼻是引起眼表疾病的重要原因，而我们目前的治疗手段往往效果不佳。 睑板腺内探针探查是一种治疗干眼症的新技术，尽管其在酒渣鼻眼表疾病的治疗中尚未得到描述。
患有眼型酒渣鼻、睑板腺功能障碍和表面疾病且对常规治疗方法有抗性的患者，接受了睑板腺内探针探查。每位患者在术前和术后 1 个月及 6 个月完成眼表疾病指数（OSDI）问卷。
10 例患者（5 名男性，5 名女性；平均年龄 42.1 岁）的 40 只眼睑接受了睑板腺内探针探查。所有患者均报告说，他们的不适、流泪和视力模糊等症状有所改善。术前、术后 1 个月和 6 个月的 OSDI 评分分别为 78.11（标准差 [SD] = 5.33）、37.54（SD = 7.25）和 43.00（SD = 5.49）。术前与术后 1 个月和 6 个月评分之间的差异具有统计学意义（p < 0.05）。本研究中的 10 例患者中有 9 例在手术后能够停止使用多西环素，10 例患者报告说减少了人工泪液的使用频率。在 6 个月的随访期间未发现任何并发症。
睑板腺内探针探查是一种安全、有效的技术，可以解决与眼型酒渣鼻相关的眼表疾病、流泪和不适，这种干预措施显著改善了这些症状。本研究首次记录了这些发现，并代表了在同行评审文献中首次对睑板腺内探针探查的使用进行定量证明。
